St. Louis-based Ascension Ventures and Labcorp have invested in a strategic financing round for Cofactor Genomics.
The company’s flagship test, OncoPrism, uses machine learning to analyze tumors and predict how they will respond to immunotherapy drugs.
“We partner with companies that can meaningfully impact care delivery across our health system partners,” said John Kuelper, senior managing director of Ascension Ventures, in a Dec. 15 news release. “Cofactor’s technology has the potential to change how immunotherapy decisions are made for a significant portion of U.S. cancer patients.”
